Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 79
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 80 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically proven, untreated diffus large B-cell lymphoma (DLBCL)
- •diagnosis between 2005 - 2019
- •age ≥80 at diagnosis
排除标准
- •diagnosis revision at a later timepoint
结局指标
主要结局
Progression-free survival (PFS)
时间窗: through study completion, an average of 2 years
time from diagnosis to death or progression/relapse
Overall survival (OS) death or progression/relapse, progression/relapse or treatment discontinuation.
时间窗: through study completion, an average of 2 years
time from diagnosis to death
Event-free survival (EFS)
时间窗: through study completion, an average of 2 years
defined as time from diagnosis to death or progression/relapse or treatment discontinuation.
次要结局
- Relative Dose intensity(within the treatment period, up to 36 weeks)
研究者
Konstantinos Christofyllakis
Consultant
University Hospital, Saarland